| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| Badawi Paul | President and CEO, Director, 10%+ Owner | C/O SIGHT SCIENCES, INC., 4040 CAMPBELL AVE., SUITE 100, MENLO PARK | /s/Jeremy Hayden, Attorney-in-Fact for Paul Badawi | 21 Jan 2026 | 0001870865 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | SGHT | Common Stock | Sale | $148,036 | -22,362 | -0.37% | $6.62 | 6,025,840 | 16 Jan 2026 | Direct | F1, F2, F3, F4 |
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
| Id | Content |
|---|---|
| F1 | Reflects shares of the Issuer's common stock, par value $0.001 per share ("common stock"), sold to cover the Reporting Person's tax liability in connection with the vesting of restricted stock units. |
| F2 | Reflects the weighted average price at which the shares of common stock were sold. The shares were sold in multiple transactions at prices ranging from $6.44 to $6.69, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| F3 | Includes (i) 5,517,778 shares of common stock, and (ii) 508,062 shares of common stock which shall be acquired upon the vesting and settlement of restricted stock units ("RSUs") that have not yet vested. |
| F4 | The Reporting Person previously reported a grant of 87,800 RSUs on a Form 4 filed on February 11, 2022 (which was subsequently included under Table 1 on a Form 4 filed on January 5, 2023) and a grant of 176,600 RSUs on a Form 4 filed on March 21, 2023, which were awarded on February 9, 2022 and March 16, 2023, respectively. Of these RSU grants, 176,500 shares were inadvertently excluded from the Reporting Person's beneficially owned shares. The reported balance includes these previously excluded shares. Furthermore, the Reporting Person's Form 4 filed on February 16, 2024 inadvertently included under Column 5 of Table I 53,574 shares of common stock underlying the Reporting Person's stock options that were to vest within 60 days of the date of such filing. The reported balance on this Form 4 excludes the number of shares underlying such stock options. |